Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.

about

Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine Current recommendations and emerging options for the treatment of allergic rhinitis.

P2860

Q26750723-40D157B3-5C61-47C6-BA81-E71B452A40AC Q38250070-75B7DA39-6D8A-4F22-98B5-687CF919F5CD

P2860

Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.

Item

http://www.wikidata.org/entity/Q42052228

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Bilastine: a new nonsedating o ...... oconjunctivitis and urticaria.

@en

Bilastine: a new nonsedating o ...... oconjunctivitis and urticaria.

@nl

type

Item

label

Bilastine: a new nonsedating o ...... oconjunctivitis and urticaria.

@en

Bilastine: a new nonsedating o ...... oconjunctivitis and urticaria.

@nl

prefLabel

Bilastine: a new nonsedating o ...... oconjunctivitis and urticaria.

@en

Bilastine: a new nonsedating o ...... oconjunctivitis and urticaria.

@nl

P1476

Bilastine: a new nonsedating o ...... oconjunctivitis and urticaria.

@en

P2093

Ole D Wolthers

http://www.w3.org/2001/XMLSchema#string

P2860

Industry sponsorship and research outcome

In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist.

Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers.

Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis.

New insights into the second generation antihistamines.

Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.

Allergic rhinitis and its impact on asthma.

Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity.

The role of histamine in allergic disease: re-appraisal of its inflammatory potential.

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).

P304

626837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2013/626837

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2013

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255977013

http://www.w3.org/2001/XMLSchema#string

P698

23956994

http://www.w3.org/2001/XMLSchema#string

P921

histamine antagonist

rhinoconjunctivitis

P932

3728546

http://www.w3.org/2001/XMLSchema#string

Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.

about

P2860

P2860

Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P921

P932